GENI vs SRAD: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

SRAD is the larger of the two ($3.50B market cap): the incumbent the market prices for continued execution (25.84x forward earnings, beta 1.63). GENI is the smaller challenger ($1.48B), cheaper on forward earnings (5.22x): more room to run, but more to prove. On the numbers, GENI leads on both counts: faster expected revenue growth (25% vs 5%) and a lower forward P/E (5.22x vs 25.84x). The case for SRAD rests on its own driver (Duopoly moat in official sports data): if you believe in that, SRAD fits; if you believe in what the numbers show today, GENI does.

GENI vs SRAD: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricGENISRADWhat it tells you
Market cap$1.48B$3.50BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E5.2225.84Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta1.881.63Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range22% of range3% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book2.1615.04How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Reading it: GENI is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how GENI and SRAD affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. GENI and SRAD share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined GENI and SRAD exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Genius Sports (GENI) do?

Genius Sports Limited is a sports data and technology company incorporated in Guernsey, headquartered in London, and listed on the New York Stock Exchange since its 2021 SPAC combination. The model has three linked parts. It signs exclusive rights with leagues and federations to collect their official real-time data, it distributes that data plus trading and streaming products to regulated sportsbooks, and it supplies technology back to the leagues themselves, which is often how the rights get paid for. Its anchor asset is the NFL, where Genius is the exclusive distributor of official data feeds and operates BetVision, the low-latency watch-and-bet product embedded inside sportsbook apps. That partnership was extended and widened and now runs through the end of the 2029 NFL season, and it lets Genius monetise advertising inventory against the BetVision streams; in October 2026 Genius also began feeding official real-time NFL data to NFL Gametime on X. Beyond the NFL, the rights portfolio spans several hundred competitions including English football and FIBA basketball.

Full GENI guide

What does Sportradar Group AG (SRAD) do?

Sportradar Group AG (Nasdaq: SRAD) is a B2B sports technology company that collects, models, and distributes real-time sports data. It sits between the leagues (from whom it licenses official data rights across soccer, tennis, basketball, and more) and its customers (sportsbooks, casinos, media companies, and leagues themselves), supplying live odds, managed trading services, integrity monitoring, and advertising and marketing tools. Crucially, Sportradar does not take bets or act as a bookmaker, so its economics track the overall growth of regulated betting rather than the win-or-lose outcome of any single wager. Its 2024 acquisition of IMG ARENA's global betting rights portfolio deepened its official-data moat.

Full SRAD guide

GENI vs SRAD: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • GENI drivers: The NFL contract and BetVision; Legend and the pivot into owned media.
  • SRAD drivers: Duopoly moat in official sports data; Margin expansion and cash generation.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The dominant structural risk is rights renewal: Genius does not own the sports, it rents them, and every renewal is an auction that Sportradar and others can bid up until the contract stops being profitable. For SRAD, the largest risk is the cost of official league data rights, which come up for renewal every several years and are increasingly priced in cash plus equity stakes, diluting shareholders and pressuring margins.

GENI or SRAD: which should you pick?

If the story you believe is GENI's (The NFL contract and BetVision), GENI is the more direct way to own it; if it is SRAD's (Duopoly moat in official sports data), SRAD is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the GENI and SRAD guides.

GENI vs SRAD: the full fundamentals

GENI. At roughly $1.48 billion the market cap is about 1.7x trailing revenue and roughly 1.4x the midpoint of guided 2026 revenue, or about 5x guided adjusted EBITDA before adding the roughly $615 million of net debt, which lifts the enterprise value multiple to around 7x. That is lower than in October, when the shares were near $6.42, and it is still being paid on an adjusted figure while GAAP results are loss-making. Analysts tracked by Yahoo have a mean target near $10.24, and Oppenheimer cut its target to $10 from $12 after Q3 while keeping Outperform. Figures are approximate and tied to the asOf date, so check live numbers and the latest 6-K before drawing conclusions.

SRAD. SRAD closes near $11.85 on November 20, 2026, down about 49% year to date and close to its 52-week low of about $11.39. Thin reported earnings push the trailing P/E to about 169x, while the forward P/E is about 26x and the stock trades at about 2.4x sales and about 21x EV/EBITDA. The gap between strong cash generation and weak reported profit is what the market is pricing, and the Q3 beat with reiterated guidance has not yet moved the shares off their lows.

Headline figures (approximate, November 2026): GENI shows revenue (ttm) ~$894 million, q3 2026 revenue ~$270 million, up ~62% year over year and ahead of ~$260 million guided; adjusted EPS $0.14 vs $0.20 expected, q3 2026 adjusted ebitda ~$87 million (~32% margin) against ~$85 million guided; free cash flow ~$54 million, fy2026 guidance (raised nov 5, 2026) ~$1.015 billion to ~$1.035 billion revenue, ~$287 million to ~$297 million adjusted EBITDA; ~$260 million year-end cash; SRAD shows revenue (ttm) ~€1.46B, q3 2026 revenue ~€362.5M (~+24% YoY), q3 2026 eps vs estimate $0.16 vs ~$0.10, operating / net margin ~14% / ~1.5%.

The bottom line: GENI vs SRAD

GENI and SRAD are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined GENI and SRAD exposure against your real portfolio. It is not an investment adviser.

Wondering how GENI or SRAD fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Genius Sports

Ask Walnut's AI anything about GENI and see how it fits what you own.

FAQ

What is the difference between GENI and SRAD?

+

Genius Sports Limited is a sports data and technology company incorporated in Guernsey, headquartered in London, and listed on the New York Stock Exchange since its 2021 SPAC combination. Sportradar Group AG (Nasdaq: SRAD) is a B2B sports technology company that collects, models, and distributes real-time sports data. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is GENI or SRAD the better stock?

+

Neither is universally better. SRAD is the larger incumbent; GENI is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, GENI or SRAD?

+

On forward P/E (as of November 2026), GENI trades at 5.22x and SRAD at 25.84x, so GENI is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both GENI and SRAD?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of GENI vs SRAD?

+

GENI: The dominant structural risk is rights renewal: Genius does not own the sports, it rents them, and every renewal is an auction that Sportradar and others can bid up until the contract stops being profitable. Customer concentration compounds it, because a handful of large sportsbooks generate a substantial share of Betting revenue and any one of them insourcing trading or data would be difficult to replace. Reported profitability remains negative, with a trailing net loss near $169 million even though the Q3 2026 loss narrowed to about $15.7 million, so the equity story currently rests on adjusted EBITDA, a measure that excludes share-based compensation and acquisition costs. The Legend deal added about $821 million of debt on the balance sheet, contingent consideration tied to performance targets and integration work, and its affiliate sites depend on search traffic that a Google algorithm change can reduce without warning. The share count has also grown, and short interest has been elevated. The roughly 49% fall in the stock during 2026, including a drop after a Q3 report that beat revenue guidance but missed the adjusted EPS consensus ($0.14 vs $0.20), shows how much the market discounts these risks. Regulatory shifts such as Brazil's September 2026 ban on fixed-odds betting, higher betting taxes on operators, and the growth of prediction-market exchanges that sit outside the traditional sportsbook customer base are all outside the company's control. SRAD: The largest risk is the cost of official league data rights, which come up for renewal every several years and are increasingly priced in cash plus equity stakes, diluting shareholders and pressuring margins. That cost is visible now: Q3 2026 sport rights expenses rose to about €112 million from about €73 million a year earlier, and finance costs rose on the added rights. Losing a major rights contract, especially for a top U.S. league, to Genius Sports would be a serious blow to Sportradar's competitive position and valuation. The company reports in euros while a large share of growth is U.S. dollar-denominated, so foreign-exchange swings can mask underlying performance (Q3 carried a €6.4 million currency loss, mostly unrealized), and Q1 and Q2 2026 both showed small net losses before the Q3 profit. Managed Betting Services revenue fell 3% in Q3 on unfavorable sport outcomes, a reminder that part of the business does carry trading risk. Restructuring costs (€4.5 million in Q3) and litigation costs also weigh on reported earnings. Regulatory risk cuts both ways: tighter betting rules can shrink the market, while unsettled prediction-market rules make that upside speculative. Sportradar has also drawn short-seller scrutiny (including a Bear Cave report) and faces the longer-term threat that raw sports data becomes commoditized. Sentiment is a risk in its own right: the stock is down about 49% year to date as of November 20, 2026 and has not recovered after the Q3 beat, and some analysts have favored Genius Sports instead.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell GENI or SRAD; figures are approximate and dated (as of November 2026). Verify current data before investing.